Amsterdam, The Netherlands, 18 August 2015. LSP (Life Sciences Partners), a leading European investor in health care, announces its investment in Kuros, a private, late-stage company developing novel, biomaterial based combination therapies in the fields of sealants and orthobiologics. Its late stage pipeline has generated highly positive data in multiple clinical studies. A PDF version of Kuros' press release can be found here.
About LSP
LSP (Life Sciences Partners) is a leading independent European investment firm, providing financing for private and public life-science companies. Since the late 1980s, LSP’s management has invested in a large number of highly innovative enterprises, many of which have grown to become leaders of the global life-science industry. With over USD 1 billion of investment capital raised to date and offices in Amsterdam, Munich and Boston, LSP is one of Europe’s largest and most experienced specialist life-science investors. For more information, please visit www.lspvc.com.